Pacira Pharma (PCRX) Tops Q3 EPS by 20c

Pacira Pharma (NASDAQ: PCRX) reported Q3 EPS of $0.35, $0.20 better than the analyst estimate of $0.15. Revenue for the quarter came in at $62.2 million versus the consensus estimate of $60.44 million.

Pacira ended the third quarter of 2015 with cash and cash equivalents, short-term investments and long-term investments (“cash”) of $164.4 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.

You May Also Be Interested In

• Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
• Piper Sandler defends Oracle ahead of earnings, sees $2.2 billion OCI upside
• Tepper’s Appaloosa soars 32% in H1 on prescient memory-chip bets - report